Expanded Access Program for IMMU-132

Sponsor: Gilead Sciences

Expanded Access

Approved for Marketing

Sponsor score: 60

Inactive

ClinicalTrials ID:NCT04320693

This program is designed to provide eligible patients with access to the drug IMMU-132, which is not yet widely available.

Patient Parameters

Parameter	Options

Program Overview

The Expanded Access Program (EAP) allows patients who meet certain criteria to receive IMMU-132, a drug that is not yet approved for general use. This program is intended to help patients who may benefit from this treatment before it becomes more widely accessible.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.